MIAMI & JERSEY CITY, N.J.--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc. announced today that it has filed a lawsuit in the U.S. District Court of Delaware against Alvogen, Inc. and Alvogen Pine Brook, LLC. (collectively, “Alvogen”) for patent infringement.
Alvogen is seeking approval to market and sell a generic version of Minivelle® (estradiol transdermal system) prior to the expiration of two of Noven’s Orange Book listed patents (U.S. Patent Nos. 9724310 and 9730900). The lawsuit reflects Noven’s commitment to vigorously enforce its intellectual property rights against infringement.
Regarding this filing, Michael Greene, Noven’s General Counsel, stated, “Minivelle® is Noven’s premier commercialized product. We are confident in the strength of our patent position and it is our intent to aggressively protect Minivelle® and our intellectual property. Any launch by Alvogen of a generic version of Minivelle® prior to resolution of the patent litigation should be considered an `at-risk' launch, which could subject Alvogen to significant damages among other remedies.”
About Noven
Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of prescription pharmaceutical products. Noven’s mission is to develop and offer pharmaceutical products that meaningfully benefit patients around the world, with a commitment to advancing patient care through transdermal drug delivery. Noven is a stand-alone operating subsidiary of Japan-based Hisamitsu Pharmaceutical Co., Inc., serving as Hisamitsu’s U.S. platform in prescription pharmaceuticals, and helping Hisamitsu bring the benefits of patch therapy to the world. For more information about Noven, visit www.noven.com. For information about Hisamitsu, visit www.hisamitsu.co.jp/english.